{"id":"W4401363835","doi":"10.1093/oncolo/oyae181.036","title":"35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University Medical Centre; Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Lenvatinib; Medicine; Cabozantinib; Internal medicine; Renal cell carcinoma; Oncology; Cohort; Pembrolizumab; Discontinuation; Sorafenib; Cancer; Hepatocellular carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174627,0.0001076928,0.0004751622,0.0004779393,0.0002133496,0.000607031,0.0002362344,0.0002383441,0.001030666],"category_scores_gemma":[0.002160142,0.00008364323,0.0006952719,0.0007811055,0.0001666261,0.0003419313,0.0002721263,0.000388664,0.0001522564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005587419,"about_ca_system_score_gemma":0.0004365033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00112628,"about_ca_topic_score_gemma":0.001700827,"domain_scores_codex":[0.9990165,0.0002796493,0.0001427429,0.0002251909,0.0002024966,0.0001334166],"domain_scores_gemma":[0.9970384,0.0006556263,0.001728998,0.0001094762,0.0001934954,0.0002740133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00149853,0.0001290216,0.987841,0.00006404395,0.0002089975,0.0001050363,0.00002348723,0.0002489257,0.0004425072,0.00002784468,0.0001820447,0.009228607],"study_design_scores_gemma":[0.00006827623,0.00134771,0.9963177,0.00001497085,0.0001695868,0.000498088,0.00003484327,0.0003883907,0.0003816457,0.00003332793,0.0007396241,0.000005836337],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960912,0.002286537,0.00007828786,0.00004611493,0.000005638467,0.0000198374,0.0008473296,0.000003769277,0.0006214109],"genre_scores_gemma":[0.9991346,0.0001697398,0.0000436921,0.00002373292,0.00001096712,0.000008749893,0.0005403039,8.978271e-7,0.00006742421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001174627,"threshold_uncertainty_score":0.006212115,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01513811120652536,"score_gpt":0.2673251085670865,"score_spread":0.2521869973605612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}